Cargando…
Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on <sup>11</sup>C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077372/ https://www.ncbi.nlm.nih.gov/pubmed/33976628 http://dx.doi.org/10.1159/000514191 |
_version_ | 1783684870784942080 |
---|---|
author | Kitajima, Kazuhiro Yamamoto, Shingo Fujiwara, Masayuki Kawanaka, Yusuke Yamada, Yusuke Nagasawa, Seiji Shimatani, Kimihiro Hanasaki, Takeshi Taguchi, Motohiro Kanematsu, Akihiro Yamakado, Koichiro |
author_facet | Kitajima, Kazuhiro Yamamoto, Shingo Fujiwara, Masayuki Kawanaka, Yusuke Yamada, Yusuke Nagasawa, Seiji Shimatani, Kimihiro Hanasaki, Takeshi Taguchi, Motohiro Kanematsu, Akihiro Yamakado, Koichiro |
author_sort | Kitajima, Kazuhiro |
collection | PubMed |
description | We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on <sup>11</sup>C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal <sup>11</sup>C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. <sup>11</sup>C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC. |
format | Online Article Text |
id | pubmed-8077372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-80773722021-05-10 Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT Kitajima, Kazuhiro Yamamoto, Shingo Fujiwara, Masayuki Kawanaka, Yusuke Yamada, Yusuke Nagasawa, Seiji Shimatani, Kimihiro Hanasaki, Takeshi Taguchi, Motohiro Kanematsu, Akihiro Yamakado, Koichiro Case Rep Oncol Case Report We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on <sup>11</sup>C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal <sup>11</sup>C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. <sup>11</sup>C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC. S. Karger AG 2021-03-22 /pmc/articles/PMC8077372/ /pubmed/33976628 http://dx.doi.org/10.1159/000514191 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Kitajima, Kazuhiro Yamamoto, Shingo Fujiwara, Masayuki Kawanaka, Yusuke Yamada, Yusuke Nagasawa, Seiji Shimatani, Kimihiro Hanasaki, Takeshi Taguchi, Motohiro Kanematsu, Akihiro Yamakado, Koichiro Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title | Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_full | Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_fullStr | Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_full_unstemmed | Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_short | Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_sort | accurate monitoring of the response of bone metastases to treatment in patients with prostate cancer using choline pet/ct |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077372/ https://www.ncbi.nlm.nih.gov/pubmed/33976628 http://dx.doi.org/10.1159/000514191 |
work_keys_str_mv | AT kitajimakazuhiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT yamamotoshingo accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT fujiwaramasayuki accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT kawanakayusuke accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT yamadayusuke accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT nagasawaseiji accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT shimatanikimihiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT hanasakitakeshi accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT taguchimotohiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT kanematsuakihiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT yamakadokoichiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct |